

Investor Newsletter

Issue **02** 2018



Study Shows Patients with MicroPort®'s Medial-Pivot Knee Are More Likely to Forget They've Had a Joint Replacement

(MicroPort®'s medial-pivot knee was designed to provide more stability and replicate the natural kinematics of the Knee)

MicroPort Orthopedics Inc. announced that The Journal of Arthroplasty has published a retrospective, comparative study that evaluated patient satisfaction after total knee arthroplasty ("TKA") using the MicroPort® Orthopedics' Evolution® Medial-Pivot ("MP") Knee System and a posterior-stabilized ("PS") knee system. The study showed that patients who underwent the MP-TKA scored significantly better on the Forgotten Joint Score ("FJS") than those who underwent the PS-TKA, particularly with regard to deep knee flexion and stability of the prosthesis.

The article is titled, "A Retrospective Comparison of a Medial Pivot and Posterior-Stabilized Total Knee Arthroplasty with Respect to Patient-Reported and Radiographic Outcomes," and a total of 164 patients, 76 in the MP-TKA group and 88 in the PS-TKA group, were evaluated at one-year follow-up using the FJS, a recently developed, validated measure of patient satisfaction after TKA. The FJS score is based on a 12-item questionnaire related to patients' ability to forget their artificial joint in everyday life. To date, this study is the first to compare an MP-TKA and a PS-TKA using the FJS as a primary outcome measure.

Studies show that around 20 percent of patients are not satisfied with the outcome of their total knee replacement as a result of residual pain and functional issues that can often attributed to implant design. Based on the results of this study as well as previous studies showing 95% patient satisfaction and 98.8% survivorship at 17 years, it is clear that the unique design of the MP-TKA can deliver reproducible outcomes that drive patient satisfaction. Furthermore, it is the only system on the market with a clinically-proven 20-year history.



MicroPort® Single-channel ECG Recorder Becomes the First Product Approved According to the Registration Policy

Single-channel ECG Recorder of YuanXin Corp., a wholly owned subsidiary of Shanghai MicroPort Medical Group Co., ("MicroPort®"), gained approval from Shanghai Food and Drug Administration ("SHFDA"). It is the first product approved according to the Registration Policy that was newly come into effect.



Currently, several domestic and overseas companies are developing devices similar to MicroPort® EP's Single-channel ECG Recorder, which means the first device to gain regulatory approval will enjoy first mover advantages. As a startup company focused on R&D, YuanXin Corp doesn't have manufacturing capabilities though it owns the technology. And according to the previous policies, its Single-channel ECG Recorder would by no means obtain approval so quickly. Thanks to the new Registration Policy, Shanghai Food and Drug Administration offered a special fast track procedure to the Single-channel ECG Recorder in which it checked the product and the company's production licenses at the same time, which shortened the approval time by 82% to merely 26 business days. Such innovative policy allows the Single-channel ECG Recorder to receive regulatory approval one year earlier than expected, and saved around one million yuan of productive investment for the company. It is reported that the Single-channel ECG Recorder is the only device of its kind with data management software and server front-end software that has gained the approval from SHFDA.



MicroPort® Signs Strategic Agreement with **Wuhan Asian Industrial**

MicroPort® reached a strategic agreement with Wuhan Asian Industrial Co, Ltd. ("Wuhan Asian Industrial") in order to cooperate in the research and development of new technology and new product in the medical device industry. The two parties will strengthen their cooperation in clinical study and technology to better foresee the industry development trend and identify unsatisfied clinical needs. At the same time, the bilateral cooperation will help promoting the development of the industrialization projects. According to the agreement, the relatively mature techniques that Wuhan Asian Industrial acquired from its clinical study will be shown to and evaluated by MicroPort®, which will then provide its assessment advice on industrialization. The two parties will actively explore and implement possible industrialization projects by sharing resources and leveraging complementary advantages in R&D and clinical study.


03



MicroPort® Attends MD&M WEST 2018

MicroPort® attended the 2018 Medical Design & Manufacturing West ("MD&M WEST") with its subsidiary Shanghai MicroPort D-Pulse Medical Co., Ltd. ("MicroPort® D-Pulse") and Dongguan Kewei Medical Instrument Co., Ltd. ("Dongguan Kewei") to display their products and OEM/ODM samples.

MD&M WEST is the world's largest annual expo of medical device and medical device design software, which has been held for 33 years. This year, the medtech event gathered more than 2,200 exhibitors and 20,000 attendees. During the expo, the visitors said they were impressed by the products and the production capacities of MicroPort® and its subsidiaries. General Manager of MicroPort® D-Pulse Dr. Jiahong Tan introduced the surgical accessories to overseas distributors and achieved initial intent of cooperation with the clients from US, Mexico, Brazil, Poland, Iran, South Korea, Japan, and Taiwan. It was the first appearance of MicroPort® D-Pulse in an international congress, which is expected to help promote its technology and products and raise the awareness of its brand. At the same time, Dongguan Kewei displayed its arterial cannula, venous cannula, suction tube, and infusion tube of the extracorporeal circulation machine, as well as the occluders. It attracted attention from several of distributors from US, Mexico, Brazil, and etc. which would help to increase the awareness of the Dongguan Kewei brand and help cultivate the American markets.





MicroPort® EP Attends the 10th VAS-CHINA

The Columbus™ 3D EP Navigation System ("Columbus™") that developed by Shanghai MicroPort EP MedTech Co., Ltd. ("MicroPort® EP") impressed attendees of the 10th Ventricular Arrhythmia Symposium ("VAS-CHINA") in Nanjing, Jiangsu Province with its outstanding performance in tackling ventricular arrhythmias.

Ventricular arrhythmia is a common arrhythmia. Ventricular tachycardia, flutter and fibrillation are the main causes of sudden cardiac death. Effective prevention of ventricular arrhythmia has great clinical significance in preventing sudden cardiac death. Columbus™ is the first domestically developed 3D EP navigation system that features real time electromagnetic device tracking with cardiac motion compensation. It is also the only domestically made 3D EP navigation system with the CE certificate, which has won high recognition from domestic experts for its outstanding performance. As the only domestic company that provides a complete solution of cardiac EP treatment, MicroPort® EP will continue to strive for innovation and perfection to provide better arrhythmia solutions for patients and physicians.



Investor Newsletter

Issue **02** 2018



For more information, please contact:

Martin Sun

Chief Financial Officer
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com

Leanne Li

Board Secretary & VP of Corporate General Affairs
MicroPort Scientific Corporation

Tel: (86)(21) 38954600

Email: ir@microport.com